Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight
Sign up
now
|
|
|
To reach top decision makers in health care, advertise in
IN VIVO, Medtech Insight, START-UP, and The RPM Report.
| Call us
today for more information: |
Ken
May
Director, Commercial Sales
Elsevier Business Intelligence |
Tel: (914) 332-1419
Mobile: (914) 356-5107
Email: k.may@elsevier.com |
|
|
 |
IN VIVO reaches top decision makers in the global health care marketplace with an authority no other publication can match.
IN VIVO has a 100% paid circulation base (annual subscription cost: $1550). The 10,000+ executives who get
IN VIVO every month read it because IN VIVO delivers unparalleled insight and analysis on company strategy, marketplace trends, key industry developments, and dealmaking.
|
Your advertisement in IN VIVO is delivered:
- To the highest level readership of key decision makers at health care products companies
- In a context unparalleled for credibility and insight
- At a cost significantly lower than other industry publications
View on-line media kit for IN VIVO advertising rates and demographics
(Adobe PDF Format)
 |
START-UP delivers your message to senior executives with committed interests in the emerging medical marketplace.
The 3,500+ executives who get START-UP every month read it because START-UP delivers expert analysis on the hottest companies, technologies, and trends affecting the emerging medical marketplace.
|
START-UP has 100% paid circulation base (annual subscription cost: $1350). Your advertisement in START-UP is delivered:
- To the highest level readership of key decision makers at health care products companies
- In a context unparalleled for credibility and insight
- At a cost significantly lower than other industry publications
View on-line media kit for START-UP advertising rates and demographics
(Adobe PDF Format)
 |
Medtech Insight newsletter delivers the highest quality content on medical technologies impacting the spectrum of surgical, orthopedic, cardiovascular and many other markets.
Top executives and investment professionals demand the Medtech Insight newsletter because it captures the perspectives of respected industry analysts, industry insiders, and clinicians to provide high-quality insights and analyses into the technologies impacting today’s global medical device marketplace.
|
Drivers and Opportunities for Novel Medical Technologies
Converging Medical Device, Biotech & Pharma Markets
Exclusive Content on Current & Emerging Medical Technologies
Latest Insider Information
Medtech Insight is published 10 times a year (including two combined issues)
View on-line media kit for Medtech Insight advertising rates and demographics
(Adobe PDF Format)
 |
The RPM Report: Regulation, Policy and Market Access delivers Biopharmaceutical executives engaged in gaining market access for their products. This 100% paid-circulation publication provides vital information on the regulatory, reimbursement and policy requirements to achieve commercial success.
|
View on-line media kit for The RPM Report advertising rates and demographics
(Adobe PDF Format)
|
|
 |
|
 |
|
|
| |
 |
Biopharma Trends: Nowhere To Go But Up
Biopharmaceutical trends in 2008 were fundamentally altered by the global financial crisis. And 2009's events were similarly impacted by the ongoing recovery. . . [MORE] (IN VIVO)
The A-List: 2009's Trend-Shaping Series A Financings
New company creation slipped significantly in 2009 as venture capitalists conserved capital and supported existing portfolio companies. . . [MORE] (Start-Up)
Stent Market Doldrums Push Interest Elsewhere
The new realities of the drug-eluting stent market are evident in recent sales results from the big competitors, driving many of them to branch into other higher growth areas. . . [MORE] (Medtech Insight)
The Future of Pharma: The Scale to Fail
The pharmaceutical sector saw a wave of major consolidation in 2009. There are a number of lessons to be learned from the M&A activity that can be applied to the New Year, including the increasing need to get bigger in order to absorb the R&D misses. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|
